Dec 28, 2025 • Finviz
BULLISH
CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update
CRISPR Therapeutics has released promising clinical data for zugo-cel, an investigational allogeneic CAR T therapy. The therapy shows a strong 90% overall response rate and 70% complete response rate in large B-cell lymphoma, along with rapid B-cell depletion and lupus remission in autoimmune disease trials. These results highlight zugo-cel's potential across both oncology and autoimmune conditions.
Dec 27, 2025 • ts2.tech
SOMEWHAT-BULLISH
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts
CRISPR Therapeutics (CRSP) stock is being influenced by ARK Invest's recent share purchases and investor digestion of new zugo-cel pipeline data. Despite a CFO insider sale, the market is balancing headline momentum with long-term risks, especially with key clinical updates for zugo-cel expected in late 2026. Analysts maintain a "Hold" consensus, but some see significant upside.
Dec 27, 2025 • Investing.com
BULLISH
Cathie Wood’s ARK boosts CRISPR stock with significant buy
Cathie Wood's ARK ETFs made a significant purchase of CRISPR Therapeutics AG (NASDAQ:CRSP) stock, acquiring 23,170 shares across its ARKK and ARKG ETFs for a total of $1,313,970. This continues a trend of consistent buying throughout the week, signaling strong conviction in the biotech company. ARK also engaged in other trades, including selling Ibotta Inc and buying WeRide Inc and Pacific Biosciences of California Inc, reflecting its focus on innovative biotech and tech sectors.
Dec 26, 2025 • Finviz
SOMEWHAT-BULLISH
These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026?
In 2025, CRISPR Therapeutics and HCA Healthcare significantly outperformed the S&P 500, with CRISPR rising 44% and HCA Healthcare 58%. The article examines whether these companies can maintain their momentum in 2026, considering CRISPR's clinical pipeline and HCA Healthcare's financial strength amid potential policy changes. It concludes that both remain attractive for investors, especially those comfortable with CRISPR's elevated risk and HCA's long-term stability.
Dec 25, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
CRISPR Therapeutics (CRSP): Reassessing Valuation After Positive Zugo‑cel Data and New Eli Lilly Collaboration
CRISPR Therapeutics (CRSP) has provided positive updates on its off-the-shelf CAR T therapy, zugo-cel, including strong early responses, clean safety signals, and a new collaboration with Eli Lilly. Despite a recent share price recovery, the stock appears undervalued according to Simply Wall St's DCF model, suggesting a potential discount of over 55% compared to its fair value estimate of $126.78. The company's price-to-book ratio is slightly higher than the US biotech industry average but significantly lower than its peer group, indicating that the market may still be discounting its growth prospects.
Dec 24, 2025 • MSN
NEUTRAL
CRISPR Therapeutics AG (CRSP) stock falls amid market uptick: What investors need to know
CRISPR Therapeutics AG (CRSP) experienced a 0.50% decline in its stock price to $66.18, underperforming the broader market's gains, with the S&P 500 rising 0.04% and the Dow up 0.11%. The stock traded below its 52-week high of $90.96 and above its 52-week low of $40.54, indicating mixed sentiment despite recent negative performance.